甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：中盘、融资融券、 基金重仓、医疗器械、多肽药等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 分红方面，甘李药业A股上市后累计派现16.12亿元。近三年，累计派现10.18亿元。 1月8日，甘李药业盘中下跌2.04%，截至14:17，报70.03元/股，成交4.71亿元，换手率1.19%，总市值 418.29亿元。 资金流向方面，主力资金净流出1526.78万元，特大单买入1465.26万元，占比3.11%，卖出3268.39万 元，占比6.94%；大单买入1.24亿元，占比26.34%，卖出1.21亿元，占比25.75%。 甘李药业今年以来股价涨2.88%，近5个交易日涨4.58%，近20日涨10.42%，近60日涨1.20%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日 ...

爱美客今年以来股价涨4.61%，近5个交易日涨4.96%，近20日涨5.01%，近60日跌15.52%。 分红方面，爱美客A股上市后累计派现38.87亿元。近三年，累计派现30.12亿元。 资金流向方面，主力资金净流入1392.40万元，特大单买入3670.19万元，占比11.66%，卖出2429.69万 元，占比7.72%；大单买入8204.36万元，占比26.06%，卖出8052.47万元，占比25.57%。 资料显示，爱美客技术发展股份有限公司位于北京市朝阳区建国路甲92号世茂大厦C座21层，成立日期 2004年6月9日，上市日期2020年9月28日，公司主营业务涉及从事生物医用软组织修复材料的研发、生 产和销售。主营业务收入构成为：溶液类注射产品57.27%，凝胶类注射产品37.97%，其他3.01%，冻干 粉类注射产品1.50%，面部埋植线0.26%。 爱美客所属申万行业为：美容护理-医疗美容-医美耗材。所属概念板块包括：合成生物、多肽药、医疗 器械、化妆品、中盘等。 截至12月31日，爱美客股东户数6.01万，较上期减少2.71%；人均流通股3472股，较上期增加2.78%。 2025年1月-9月 ...

爱美客今年以来股价涨2.03%，近5个交易日涨0.77%，近20日涨2.98%，近60日跌19.85%。 1月5日，爱美客盘中上涨2.03%，截至13:07，报144.60元/股，成交3.75亿元，换手率1.25%，总市值 437.55亿元。 资金流向方面，主力资金净流入461.07万元，特大单买入3451.55万元，占比9.21%，卖出2843.66万元， 占比7.59%；大单买入1.06亿元，占比28.36%，卖出1.08亿元，占比28.75%。 资料显示，爱美客技术发展股份有限公司位于北京市朝阳区建国路甲92号世茂大厦C座21层，成立日期 2004年6月9日，上市日期2020年9月28日，公司主营业务涉及从事生物医用软组织修复材料的研发、生 产和销售。主营业务收入构成为：溶液类注射产品57.27%，凝胶类注射产品37.97%，其他3.01%，冻干 粉类注射产品1.50%，面部埋植线0.26%。 爱美客所属申万行业为：美容护理-医疗美容-医美耗材。所属概念板块包括：合成生物、多肽药、医疗 器械、化妆品、中盘等。 截至12月19日，爱美客股东户数6.17万，较上期增加2.23%；人均流通股3378股，较上期 ...

12月18日，甘李药业盘中下跌2.02%，截至13:51，报65.45元/股，成交3.12亿元，换手率0.85%，总市值 390.94亿元。 资金流向方面，主力资金净流出2387.04万元，特大单买入2520.06万元，占比8.07%，卖出1941.13万 元，占比6.22%；大单买入6818.46万元，占比21.83%，卖出9784.44万元，占比31.33%。 甘李药业今年以来股价涨51.84%，近5个交易日涨0.28%，近20日涨4.99%，近60日跌9.96%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研发、生产和销售。 主营业务收入构成为：生物制品(原料药及制剂产品)95.05%，医疗器械及其他4.69%，特许权服务收入 0.14%，化药0.12%。 甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：中盘、基金重仓、 融资融券、医疗器械、多肽药等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股， ...

【今日速览】 ①数字孪生+元宇宙+智慧社区+军工信息化！公司已在公安、气象、交通、健康与社区服务等垂直领 域，研发与具体业务场景深度结合的专用智能体；②人形机器人+eVTOL+大飞机+通用航空+商业航 天！公司获得人形机器人加工件定点采购协议；③燃料电池+氢能+航空航天+可控核聚变+量子计 算！公司为"华龙一号"核电站提供成套混凝土冷却系统。 【臻选回顾】 公告臻选12月1日提示《恒逸石化：控股股东及其一致行动人拟15亿元-25亿元增持公司股份》， 恒逸石化12月2日高开高走封死涨停直至收盘，12月3日再度上涨3%；公告臻选12月2日提示《稀 土永磁+钨钼+锂电+核聚变！公司光伏用细钨丝市场份额超80%》，厦门钨业12月3日逆市飘红， 12月5日、8日分别上涨1.77%、3.86%；公告臻选12月2日提示《主控芯片+高端封测+存储器 +AI，公司拟定增37亿元用于面向AI领域的高端存储器等项目》，江波龙12月8日大涨14.64%；12 月3日提示《多肽药+创新药+原料药+减肥药！公司产品通过药监局化妆品新原料备案》，圣诺生物 12月4日低开高走收涨3.55%；12月4日提示《显示驱动芯片+CMOS图像传感器+ ...

面对每晚海量的公告无从下手？《公告臻选》助你高效决策！专业筛选每晚最重要的关键公告，提供通 俗易懂的深度解读，揭示复杂术语背后的投资机会。助你10分钟掌握市场全貌，决胜开盘之前。 ①多肽药+创新药+原料药+减肥药！公司五肽-18通过药监局化妆品新原料备案；②一带一路+海外 基地优势+液体黄金"技术！公司拟投资1.5亿美元建设柬埔寨项目；③区域基建龙头+国企改革+新 型城镇化+重庆本地股，公司中标近30亿元工程项目。 前言 点击解锁付费内容，捕捉每天公告中的"黄金机会"！ ...

Core Viewpoint - The stock of Taiankang has shown significant volatility, with a year-to-date increase of 100.53%, but recent trends indicate a decline over the past 20 and 60 days, raising concerns about its future performance [1][2]. Financial Performance - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, representing a year-on-year decrease of 8.13% [2]. - The net profit attributable to the parent company for the same period was 31.41 million yuan, reflecting a substantial year-on-year decline of 73% [2]. Stock Market Activity - As of November 26, Taiankang's stock price was 29.66 yuan per share, with a market capitalization of 12.62 billion yuan [1]. - The trading volume on that day was 66.90 million yuan, with a turnover rate of 0.75% [1]. - The stock has experienced a net outflow of 4.76 million yuan in principal funds, indicating a lack of strong buying interest [1]. Shareholder Information - As of September 30, the number of shareholders for Taiankang increased to 12,000, a rise of 9.32% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.53% to 25,381 shares [2]. Dividend Distribution - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].

Core Viewpoint - 博腾股份 has experienced a decline in stock price recently, despite a significant increase in its stock price year-to-date, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, 博腾股份 reported revenue of 2.544 billion yuan, representing a year-on-year growth of 19.72% [2]. - The net profit attributable to shareholders for the same period was 79.9154 million yuan, showing a substantial increase of 138.71% year-on-year [2]. Stock Market Activity - As of November 19, 博腾股份's stock price was 23.73 yuan per share, with a market capitalization of 12.896 billion yuan [1]. - The stock has seen a year-to-date increase of 50.48%, but has declined by 2.83% over the last five trading days and 3.18% over the last twenty days [1]. Shareholder Information - As of November 10, 博腾股份 had 46,700 shareholders, a decrease of 2.23% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.96% to 10,674 shares [2]. Dividend Distribution - 博腾股份 has distributed a total of 1.193 billion yuan in dividends since its A-share listing, with 866 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder was Hong Kong Central Clearing Limited, holding 23.9776 million shares, an increase of 13.2187 million shares from the previous period [3]. - New institutional shareholders include 华安聚优精选混合, which holds 3.7775 million shares [3].

Core Viewpoint - 博瑞医药's stock has experienced significant fluctuations in 2023, with a year-to-date increase of 73.80% but a recent decline in the last five trading days by 1.95% [2] Group 1: Stock Performance - As of November 18, 博瑞医药's stock price is 52.32 CNY per share, with a market capitalization of 22.137 billion CNY [1] - The stock has seen a 53.20% decline over the past 60 days [2] - The trading volume on November 18 was 1.17 billion CNY, with a turnover rate of 0.52% [1] Group 2: Financial Performance - For the period from January to September 2025, 博瑞医药 reported a revenue of 874 million CNY, a year-on-year decrease of 10.50% [2] - The net profit attributable to shareholders for the same period was 50.32 million CNY, down 71.64% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, 博瑞医药 had 19,600 shareholders, an increase of 104.44% from the previous period [2] - The average number of circulating shares per shareholder decreased by 51.05% to 21,629 shares [2] - The company has distributed a total of 246 million CNY in dividends since its A-share listing, with 129 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 8.7219 million shares, an increase of 5.471 million shares from the previous period [3] - The ninth-largest circulating shareholder is Innovation Drug, holding 2.9109 million shares, with an increase of 98,300 shares from the previous period [3]

11月14日，博瑞医药（维权）盘中上涨2.02%，截至10:39，报55.49元/股，成交3.19亿元，换手率 1.37%，总市值234.78亿元。 资金流向方面，主力资金净流入1714.71万元，特大单买入1799.70万元，占比5.65%，卖出1781.45万 元，占比5.59%；大单买入9794.36万元，占比30.73%，卖出8097.89万元，占比25.41%。 博瑞医药今年以来股价涨84.33%，近5个交易日涨4.27%，近20日涨8.17%，近60日跌51.15%。 责任编辑：小浪快报 资料显示，博瑞生物医药(苏州)股份有限公司位于江苏省苏州工业园区星湖街218号纳米科技园C25-C28 栋,香港铜锣湾勿地臣街1号时代广场2座31楼，成立日期2001年10月26日，上市日期2019年11月8日，公 司主营业务涉及研发和生产高端仿制药和原创性新药。主营业务收入构成为：产品销售收入89.90%， 技术权益及服务收入6.77%，其他(补充)3.33%。 博瑞医药所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：仿制药、生物医药、创新 药、多肽药、中盘等。 机构持仓方面，截止2025年9月3 ...